

# Seraseq® ctDNA v2 Reference Materials

Highly multiplexed next-generation sequencing (NGS)-based assays need highly multiplexed reference materials. With 40 clinically relevant mutations across 28 genes, the patient-like Seraseq ctDNA v2 standards are purpose-built to accelerate the development, validation, and clinical implementation of NGS-based liquid biopsies.

NGS-Based Assay Compatibility					
Archer® Reveal ctDNA™ 28 Kit	Oncomine® Pan-Cancer Cell-Free Assay	Oncomine Lung cfDNA Assay	Oncomine Colon cfDNA	UltraSEEK™ Colon Panel	UltraSEEK Lung Panel
AKT1 ●	AKT1 ●	ALK ●	AKT1 ●	BRAF ●	BRAF ●
ALK ▲	ALK ●▲	BRAF ●	BRAF ●	EGFR ●◇	EGFR ●◇
BRAF ●	APC ●	EGFR ●◇	EGFR ●◇	KRAS ●	ERBB2 ◇
CTNNB1 ●	BRAF ●	ERBB2 ◇	ERBB2 ◇	NRAS ●	KRAS ●
EGFR ●◇	CTNNB1 ●	KRAS ●	KRAS ●	PIK3CA ●◇	PIK3CA ●◇
ERBB2 ◇	EGFR ●◇	NRAS ●	NRAS ●		
IDH1 ●	ERBB2 ◇	PIK3CA ●◇	PIK3CA ●◇		
KIT ●	FGFR3 ●	ROS1 ▲	SMAD4 ●		
KRAS ●	FLT3 ●	TP53 ●◇	TP53 ●◇		
NRAS ●	GNA11 ●				
PDGFRA ●	GNAQ ●				
PIK3CA ●	GNAS ●				
RET ▲	IDH1 ●				
ROS1 ▲	KIT ●				
SMAD4 ◇	KRAS ●				
TP53 ●◇	NRAS ●				
	PDGFRA ●◇				
	PIK3CA ●◇				
	PTEN ●				
	TP53 ●◇				
	ROS1 ▲				
	RET ▲				

Key

SNV ●

INDEL ◇

CNV ■

Fusion ▲

Learn more at [www.seracare.com/ctDNA](http://www.seracare.com/ctDNA)